Thistlethwaite Protocol ITN025ST - Immunosuppression with Campath-1H [alemtuzumab] and tacrolimus in liver transplantation.

Trial Profile

Thistlethwaite Protocol ITN025ST - Immunosuppression with Campath-1H [alemtuzumab] and tacrolimus in liver transplantation.

Completed
Phase of Trial: Phase II

Latest Information Update: 20 May 2011

At a glance

  • Drugs Alemtuzumab (Primary) ; Tacrolimus
  • Indications Liver transplant rejection
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 Dec 2008 Updated end date as reported by ClinicalTrials.gov record.
    • 10 Dec 2008 Status changed from recruiting to completed. as reported in ClinicalTrials.gov record.
    • 02 Dec 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top